
Dec 16 (Reuters) - Monte Rosa Therapeutics Inc GLUE.O:
MONTE ROSA THERAPEUTICS ANNOUNCES COMPELLING CLINICAL ACTIVITY OF MRT-2359 IN COMBINATION WITH ENZALUTAMIDE IN HEAVILY PRETREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITH ANDROGEN RECEPTOR MUTATIONS